Sonoma Pharmaceuticals, Inc.
SNOAHealthcare|Drug Manufacturers - Specialty & Generic|US
$1.11
+0.04 (+3.74%)
Tangible Book / Share
$1.71
Cash / Share
$1.39
Financials
Financial Snapshot
Market Cap
$5.3M
Enterprise Value
$716.2K
Revenue (TTM)
$21.9M
Net Income (TTM)
-$2.3M
Cash & Investments
$5.3M
Net Cash
$4.6M
Free Cash Flow (TTM)
-$2.2M
Operating CF (TTM)
-$2.0M
Debt/Equity
0.11
Cash Runway & Burn Rate
Cash on Hand
$5.3M
Quarterly Burn
$506.8K
Monthly Burn
$168.9K
Est. Runway
~10.5 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $17.5M | $10.1M | $3.7M | $3.7M | $4.2M | $7.4M | $3.8M | $3.1M | $5.4M | $2.4M | $5.3M | |
| Operating Cash Flow | -$8.2M | -$12.4M | -$11.7M | -$4.6M | -$3.4M | -$4.2M | -$6.2M | -$2.4M | -$88.0K | -$3.9M | -$2.0M | |
| Free Cash Flow | -$8.6M | -$12.6M | -$11.8M | -$4.8M | -$3.6M | -$4.4M | -$6.4M | -$2.4M | -$168.0K | -$4.1M | -$2.2M | |
| Capital Expenditure | -$394.0K | -$187.0K | -$100.0K | -$206.0K | -$179.0K | -$137.0K | -$269.0K | -$17.0K | -$80.0K | -$192.0K | -$125.0K | |
| Financing Cash Flow | -$32.0K | $5.2M | $5.5M | $1.0M | $3.3M | $7.4M | $2.5M | $1.7M | $3.0M | $477.0K | $4.3M |
R&D Spending
R&D (TTM)
$2.3M
R&D Intensity
10.4%
R&D Growth vs Prior
+0.1%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.8M | $16.7M | $19.0M | $17.9M | $18.6M | $12.6M | $13.3M | $12.7M | $14.3M | $19.5M | $21.9M | |
| R&D Expense | $1.6M | $1.6M | $1.5M | $1.3M | $555.0K | $125.0K | $207.0K | $1.9M | $1.8M | $2.3M | $2.3M | |
| R&D % of Revenue | 12.3% | 9.5% | 8.0% | 7.5% | 3.0% | 1.0% | 1.6% | 14.7% | 12.7% | 11.6% | 10.4% | |
| SG&A | $17.1M | $19.9M | $18.6M | $14.2M | $9.5M | $9.8M | $8.8M | $7.6M | $7.4M | $7.6M | $7.7M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.8M | $16.7M | $19.0M | $17.9M | $18.6M | $12.6M | $13.3M | $12.7M | $14.3M | $19.5M | $21.9M | |
| Cost of Revenue | $7.2M | $9.3M | $10.1M | $9.8M | $12.1M | $8.6M | $8.8M | $8.0M | $8.8M | $12.1M | $13.4M | |
| Gross Profit | $5.7M | $7.3M | $8.9M | $8.1M | $6.6M | $4.0M | $4.5M | $4.7M | $5.5M | $7.4M | $8.5M | |
| R&D | $1.6M | $1.6M | $1.5M | $1.3M | $555.0K | $125.0K | $207.0K | $1.9M | $1.8M | $2.3M | $2.3M | |
| SG&A | $17.1M | $19.9M | $18.6M | $14.2M | $9.5M | $9.8M | $8.8M | $7.6M | $7.4M | $7.6M | $7.7M | |
| Operating Income | -$13.0M | -$14.2M | -$11.3M | -$7.4M | -$3.4M | -$5.9M | -$4.6M | -$4.7M | -$3.7M | -$2.5M | -$1.4M | |
| Interest Expense | $3.0K | $40.0K | $33.0K | $16.0K | $12.0K | $10.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$12.9M | -$14.3M | -$11.3M | -$3.5M | -$3.9M | -$5.4M | -$5.2M | -$5.0M | -$2.9M | -$3.4M | -$2.5M | |
| Net Income | $9.3M | -$14.3M | -$11.8M | -$3.3M | -$4.0M | -$5.1M | -$5.2M | -$4.8M | -$3.5M | -$3.2M | -$2.3M | |
| EPS (Diluted) | 197.61 | -284.66 | -127.68 | -22.40 | -23.65 | -19.17 | -15.18 | -5.32 | -2.79 | -1.89 | -1.22 | |
| EBITDA | -$12.7M | -$13.7M | -$10.9M | -$3.2M | -$3.2M | -$5.2M | -$5.1M | -$4.9M | -$2.8M | -$2.3M | -$1.6M | |
| Shares Out. (M) | 0.05 | 0.05 | 0.09 | 0.15 | 0.20 | 0.27 | 0.34 | 0.91 | 1.24 | 1.68 | 3.85 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.5M | $10.1M | $3.7M | $3.7M | $4.2M | $7.4M | $3.8M | $3.1M | $5.4M | $2.4M | $5.3M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $22.6M | $16.3M | $12.5M | $12.4M | $12.8M | $16.4M | $13.8M | $12.5M | $12.6M | $12.1M | $16.3M | |
| Total Assets | $25.5M | $19.2M | $14.4M | $14.6M | $15.0M | $18.8M | $16.2M | $14.7M | $13.7M | $14.0M | $18.1M | |
| Total Current Liabilities | $3.3M | $3.3M | $3.6M | $4.7M | $4.1M | $5.8M | $3.7M | $3.7M | $4.1M | $4.8M | $5.4M | |
| Long-Term Debt | $45.0K | $32.0K | $12.0K | $0.00 | $1.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $4.0M | $3.9M | $4.0M | $8.9M | $9.6M | $10.1M | $8.3M | $8.6M | $9.3M | $10.9M | $11.5M | |
| Stockholders' Equity | $21.4M | $15.3M | $10.5M | $5.6M | $5.4M | $8.7M | $8.0M | $6.1M | $4.4M | $3.1M | $6.6M | |
| Retained Earnings | -$143.1M | -$157.4M | -$169.2M | -$175.3M | -$179.3M | -$184.4M | -$189.5M | -$194.3M | -$197.8M | -$201.0M | -$201.3M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.2M | -$12.4M | -$11.7M | -$4.6M | -$3.4M | -$4.2M | -$6.2M | -$2.4M | -$88.0K | -$3.9M | -$2.0M | |
| Capital Expenditure | -$394.0K | -$187.0K | -$100.0K | -$206.0K | -$179.0K | -$137.0K | -$269.0K | -$17.0K | -$80.0K | -$192.0K | -$125.0K | |
| Free Cash Flow | -$8.6M | -$12.6M | -$11.8M | -$4.8M | -$3.6M | -$4.4M | -$6.4M | -$2.4M | -$168.0K | -$4.1M | -$2.2M | |
| Investing Cash Flow | $18.2M | -$201.0K | -$131.0K | $3.6M | $388.0K | -$99.0K | -$258.0K | -$2.0K | -$80.0K | -$192.0K | -$125.0K | |
| Financing Cash Flow | -$32.0K | $5.2M | $5.5M | $1.0M | $3.3M | $7.4M | $2.5M | $1.7M | $3.0M | $477.0K | $4.3M | |
| Issuance of Stock | $98.0K | $5.5M | $6.0M | $1.4M | $2.3M | $7.6M | $2.9M | $1.8M | $3.1M | $471.0K | $4.0M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.0K | $0.00 | $0.00 | |
| Net Debt Issuance | -$130.0K | -$280.0K | -$478.0K | -$347.0K | $1.0M | -$374.0K | -$894.0K | -$481.0K | -$404.0K | -$271.0K | -$270.0K | |
| Stock Based Comp. | $2.1M | $2.4M | $1.6M | $839.0K | $371.0K | $382.0K | $669.0K | $516.0K | $224.0K | $255.0K | $256.0K | |
| Net Change in Cash | $10.0M | -$7.4M | -$6.4M | $2.0K | $529.0K | $3.2M | -$3.6M | -$692.0K | $2.2M | -$3.0M | $2.4M |
Dilution Tracker
Shares outstanding grew 743.7% over 5 years — significant dilution
Shares Outstanding
5M
5-Year Share Growth
+743.7%
Stock Issuance (TTM)
$4.0M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.05 | 0.05 | 0.09 | 0.15 | 0.20 | 0.27 | 0.34 | 0.91 | 1.24 | 1.68 | 3.85 | |
| Change vs Prior % | — | 7.2% | 83.6% | 59.9% | 35.1% | 32.9% | 27.9% | 167.8% | 36.5% | 35.7% | 128.4% | |
| Stock Issuance | $98.0K | $5.5M | $6.0M | $1.4M | $2.3M | $7.6M | $2.9M | $1.8M | $3.1M | $471.0K | $4.0M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$1.0K | $0.00 | $0.00 | |
| Stock Based Comp. | $2.1M | $2.4M | $1.6M | $839.0K | $371.0K | $382.0K | $669.0K | $516.0K | $224.0K | $255.0K | $256.0K |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 44.2% | 43.9% | 46.8% | 45.3% | 35.2% | 31.6% | 33.7% | 37.3% | 38.2% | 38.0% | 38.9% | |
| Operating Margin % | -101.2% | -85.2% | -59.3% | -41.2% | -18.5% | -46.6% | -34.4% | -36.9% | -26.0% | -12.6% | -6.4% | |
| Net Margin % | 72.3% | -86.0% | -62.2% | -18.5% | -21.2% | -40.3% | -38.8% | -38.0% | -24.2% | -16.3% | -10.3% | |
| EBITDA Margin % | -98.9% | -82.5% | -57.2% | -17.9% | -17.3% | -41.4% | -38.1% | -38.1% | -19.4% | -11.9% | -7.1% | |
| FCF Margin % | -66.8% | -75.8% | -62.3% | -26.8% | -19.1% | -34.7% | -48.4% | -19.0% | -1.2% | -21.1% | -9.8% | |
| ROE % | 43.3% | -93.5% | -112.5% | -58.8% | -73.7% | -58.5% | -64.6% | -78.8% | -78.4% | -102.6% | -53.6% | |
| ROA % | 36.4% | -74.6% | -81.7% | -22.7% | -26.4% | -27.0% | -31.7% | -32.8% | -25.2% | -22.7% | -12.5% | |
| ROIC % | -38.9% | -86.9% | -99.5% | -70.7% | -29.4% | -39.2% | -34.4% | -39.1% | -37.6% | -24.1% | -9.8% | |
| R&D / Revenue % | 12.3% | 9.5% | 8.0% | 7.5% | 3.0% | 1.0% | 1.6% | 14.7% | 12.7% | 11.6% | 10.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 36.9% | 29.9% | 13.9% | -5.5% | 3.9% | -32.2% | 5.1% | -4.0% | 12.2% | 36.7% | |
| Gross Profit | 114.0% | 29.0% | 21.5% | -8.5% | -19.2% | -39.1% | 12.1% | 6.0% | 15.2% | 35.7% | |
| Operating Income | 11.8% | -9.4% | 20.7% | 34.4% | 53.3% | -70.7% | 22.4% | -2.9% | 21.1% | 33.7% | |
| Net Income | 191.3% | -254.5% | 17.7% | 72.0% | -19.4% | -28.8% | -1.3% | 6.1% | 28.5% | 8.2% | |
| EPS (Diluted) | 267.7% | -244.1% | 55.1% | 82.5% | -5.6% | 18.9% | 20.8% | 65.0% | 47.6% | 32.3% | |
| Operating Cash Flow | 6.6% | -52.3% | 5.8% | 60.8% | 26.4% | -25.8% | -44.8% | 61.0% | 96.3% | -4369.3% | |
| Free Cash Flow | 5.8% | -47.5% | 6.4% | 59.4% | 25.8% | -23.3% | -46.4% | 62.4% | 93.0% | -2355.4% | |
| R&D Expense | -12.7% | -0.1% | -3.6% | -11.8% | -58.6% | -77.5% | 65.6% | 803.9% | -3.0% | 25.2% | |
| SG&A Expense | 9.7% | 16.7% | -6.5% | -23.9% | -33.3% | 3.2% | -9.4% | -14.3% | -2.8% | 3.3% | |
| Total Assets | 84.4% | -24.6% | -24.8% | 0.8% | 2.9% | 25.7% | -13.9% | -9.2% | -7.1% | 1.9% | |
| Book Value / Share | 288.3% | -33.3% | -62.7% | -66.5% | -29.4% | 22.0% | -28.3% | -71.3% | -47.4% | -48.3% | |
| Debt | 259.6% | 34.9% | -14.1% | 78.9% | 214.7% | -48.9% | -37.9% | -28.4% | -49.8% | 176.1% | |
| Diluted Shares | -45.6% | 7.2% | 83.6% | 59.9% | 35.1% | 32.9% | 27.9% | 167.8% | 36.5% | 35.7% |
Valuation
P/E (TTM)At Loss
P/S0.24
10Y Low / Med / High0.18 / 0.81 / 4.72
P/B0.65
10Y Low / Med / High0.45 / 2.18 / 5.53
EV/EBITDAAt Loss
EV/Revenue0.03
10Y Low / Med / High0.02 / 0.65 / 3.39
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$1.71
Net Current Assets / Share
$0.99
Cash / Share
$1.39
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 6.53 | -2.33 | -1.30 | -4.38 | -6.28 | -4.18 | -1.29 | -0.58 | -0.78 | -1.13 | -0.91 | |
| P/S Ratio | 4.72 | 2.00 | 0.81 | 0.81 | 1.59 | 1.68 | 0.50 | 0.22 | 0.19 | 0.18 | 0.24 | |
| P/B Ratio | 2.83 | 2.18 | 1.46 | 2.57 | 5.53 | 2.45 | 0.83 | 0.45 | 0.62 | 1.16 | 0.65 | |
| EV/EBITDA | -3.43 | -1.73 | -1.11 | -3.62 | -8.73 | -2.92 | -0.72 | -0.05 | 0.85 | -0.87 | -0.46 | |
| EV/Revenue | 3.39 | 1.43 | 0.64 | 0.65 | 1.51 | 1.21 | 0.28 | 0.02 | -0.16 | 0.10 | 0.03 |
Analyst Estimates & Quality
Altman Z-Score
-13.67
Distress
Piotroski F-Score
4
Moderate
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 |
|---|---|---|
| Revenue | $23.9M | $27.0M |
| Net Income | -$943.0K | $117.9K |
| EPS | $-0.56 | $0.07 |
| # Analysts (EPS) | 1 | 1 |
Revenue Segments
By Product
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Animal Care | $3.2M | — | — | $2.2M | $1.7M | $1.8M |
| Human Care | $15.3M | — | — | $10.1M | $12.1M | $17.7M |
| Service | — | $349.0K | — | — | — | — |
| Shipping and Handling | — | $52.0K | $42.0K | — | — | — |
| Service And Royalty | — | — | — | $422.0K | $556.0K | — |
By Geography
| Segment | 2014 | 2015 | 2016 | 2017 |
|---|---|---|---|---|
| Europe and Other | $2.1M | $2.9M | $4.5M | — |
| MEXICO | $5.3M | $5.1M | — | — |
| UNITED STATES | $5.3M | $2.0M | — | — |
| Latin America | — | — | $4.9M | $1.3M |
| United States | — | — | $6.8M | — |